Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 77 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy				Phase IV				AVO108943 NCT00470834
	Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer				Phase III, Phase II				G050103 NCT00295802
	Phase III Randomized Trial of Suicide Gene Therapy and Prostate Cancer				Phase III, Phase II				Prostate4809 P01 CA098012, NCT00583492
	Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer				Phase III				05-007 NCT00142506
	Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma				Phase III				553 NCT00132301
	Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer				Phase III				ROLL-GUP-0205-1 UCLA-0507059-01, NCT00336934
	Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer				Phase III				CALGB-90203 NCT00430183
	A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA				Phase III				XRP6976J/3503 EudraCT#:2007-000323-17, NCT00514917
	A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-Metastatic Hormone Resistant Prostate Cancer				Phase III				D4320C00015 NCT00626548
	A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation				Phase III				ID00-381 NCT00667888


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute